STAT3 dysregulation in mature T and NK cell lymphomas
Research output: Contribution to journal › Review › Research › peer-review
Standard
STAT3 dysregulation in mature T and NK cell lymphomas. / Seffens, Angelina; Herrera, Alberto; Tegla, Cosmin; Buus, Terkild B.; Hymes, Kenneth B.; Ødum, Niels; Geskin, Larisa J.; Koralov, Sergei B.
In: Cancers, Vol. 11, No. 11, 1711, 2019.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - STAT3 dysregulation in mature T and NK cell lymphomas
AU - Seffens, Angelina
AU - Herrera, Alberto
AU - Tegla, Cosmin
AU - Buus, Terkild B.
AU - Hymes, Kenneth B.
AU - Ødum, Niels
AU - Geskin, Larisa J.
AU - Koralov, Sergei B.
PY - 2019
Y1 - 2019
N2 - T cell lymphomas comprise a distinct class of non-‐-Hodgkin’s lymphomas, which include mature T and natural killer (NK) cell neoplasms. While each malignancy within this group is characterized by unique clinicopathologic features, dysregulation in the Janus tyrosine family of kinases/Signal transducer and activator of transcription (JAK/STAT) signaling pathway, specifically aberrant STAT3 activation, is a common feature among these lymphomas. The mechanisms driving dysregulation vary among T cell lymphoma subtypes and include activating mutations in upstream kinases or STAT3 itself, formation of oncogenic kinases which drive STAT3 activation, loss of negative regulators of STAT3, and the induction of a pro-‐-tumorigenic inflammatory microenvironment. Constitutive STAT3 activation has been associated with the expression of targets able to increase pro-‐-survival signals and provide malignant fitness. Patients with dysregulated STAT3 signaling tend to have inferior clinical outcomes, which underscores the importance of STAT3 signaling in malignant progression. Targeting of STAT3 has shown promising results in preclinical studies in T cell lymphoma lines, ex-‐-vivo primary malignant patient cells, and in mouse models of disease. However, targeting this pleotropic pathway in patients has proven difficult. Here we review the recent contributions to our understanding of the role of STAT3 in T cell lymphomagenesis, mechanisms driving STAT3 activation in T cell lymphomas, and current efforts at targeting STAT3 signaling in T cell malignancies.
AB - T cell lymphomas comprise a distinct class of non-‐-Hodgkin’s lymphomas, which include mature T and natural killer (NK) cell neoplasms. While each malignancy within this group is characterized by unique clinicopathologic features, dysregulation in the Janus tyrosine family of kinases/Signal transducer and activator of transcription (JAK/STAT) signaling pathway, specifically aberrant STAT3 activation, is a common feature among these lymphomas. The mechanisms driving dysregulation vary among T cell lymphoma subtypes and include activating mutations in upstream kinases or STAT3 itself, formation of oncogenic kinases which drive STAT3 activation, loss of negative regulators of STAT3, and the induction of a pro-‐-tumorigenic inflammatory microenvironment. Constitutive STAT3 activation has been associated with the expression of targets able to increase pro-‐-survival signals and provide malignant fitness. Patients with dysregulated STAT3 signaling tend to have inferior clinical outcomes, which underscores the importance of STAT3 signaling in malignant progression. Targeting of STAT3 has shown promising results in preclinical studies in T cell lymphoma lines, ex-‐-vivo primary malignant patient cells, and in mouse models of disease. However, targeting this pleotropic pathway in patients has proven difficult. Here we review the recent contributions to our understanding of the role of STAT3 in T cell lymphomagenesis, mechanisms driving STAT3 activation in T cell lymphomas, and current efforts at targeting STAT3 signaling in T cell malignancies.
KW - JAK/STAT
KW - Lymphomagenesis
KW - STAT3
KW - T cell lymphoma
U2 - 10.3390/cancers11111711
DO - 10.3390/cancers11111711
M3 - Review
C2 - 31684088
AN - SCOPUS:85074651065
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 11
M1 - 1711
ER -
ID: 230804278